Financials data is unavailable for this security.
View more
Year on year Jilin Province Huinan Changlong Bio-pharmacy Co Ltd 's net income fell -23.43% from 193.57m to 148.21m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 23.00% to 30.60%.
| Gross margin | 75.46% |
|---|---|
| Net profit margin | 20.46% |
| Operating margin | 26.16% |
| Return on assets | 7.31% |
|---|---|
| Return on equity | 10.76% |
| Return on investment | 10.25% |
More ▼
Cash flow in CNYView more
In 2023, Jilin Province Huinan Changlong Bio-pharmacy Co Ltd increased its cash reserves by 209.98%, or 238.54m. The company earned 315.95m from its operations for a Cash Flow Margin of 37.54%. In addition the company generated 109.04m cash from investing, though they paid out 186.45m more in financing than they received.
| Cash flow per share | 0.2268 |
|---|---|
| Price/Cash flow per share | 5.78 |
| Book value per share | 3.12 |
|---|---|
| Tangible book value per share | 3.11 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.74 |
|---|---|
| Quick ratio | 1.62 |
| Total debt/total equity | 0.0529 |
|---|---|
| Total debt/total capital | 0.0502 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -23.43%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | -1.67 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -- |
